Q-Line Biotech Limited

6. Except as mentioned in 2 (a) (vii) and (viii) above, no Equity Shares have been issued at price below the Issue price within last one year from the date of the Draft Red Herring Prospectus.

7. **Details of Allotment made in the last two years preceding the date of Draft Red Herring Prospectus**

Except as mentioned in point 2 (a) (vii) and (viii) above, we have not issued any Equity Share in the last two years preceding the date of Draft Red Herring Prospectus.

<table><thead><tr><td>Date of Allotment</td><td>Number of Equity Shares</td><td>Face Value (Rs.)</td><td>Issue Price (Rs.)</td><td>Reasons for Allotment</td><td>Name of Allottees</td></tr></thead><tbody><tr><td>August 28, 2025</td><td>1,41,75,000</td><td>10/-</td><td>-</td><td>Bonus Issue in the ratio of 9:1</td><td>Refer table 2 (a) (vii) above</td></tr><tr><td>September 27, 2025</td><td>5,24,999</td><td>10/-</td><td>10/-</td><td>Right Issue</td><td>Refer table 2 (a) (viii) above</td></tr></tbody></table>

8. We have not revalued our assets since inception and have not issued any Equity Shares (including bonus shares) by capitalizing any revaluation reserves.

9. The issuer company is in compliance with the Companies Act, 2013 with respect to issuance of securities since inception till the date of filing of Drat Red Herring Prospectus.

75